Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	TMPRSS6	Synonyms	IRIDA, MT2	Type of gene	protein-coding
Chromosome	22	Map location	22q12.3	dbXrefs
Gene perturbation-related omics dataset	PertOrg
Description	transmembrane serine protease 6

GTO ID	GTC2464
Trial ID	NCT04559971
Disease	Myeloproliferative Neoplasm \| Iron-Loading Anemias
Altered gene	TMPRSS6
Therapeutic/Target gene	Target gene
Therapy	siRNA
Treatment	SLN124
Phase	Early_Phase1
Recruitment status	Completed
Title	A Randomised, Double-blind, Placebo-controlled Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SLN124 in Healthy Volunteers
Year	2020
Country	United Kingdom
Company sponsor	Silence Therapeutics plc
Other ID(s)	SLN124-003

Vector information

Vector	GalNAc

Clinical Result

Cohort1: SLN124_dose level 1

Administration route	subcutaneous injection
Dosage	SLN124, 1.0 mg/kg
Pts	6
Age	Adult
References	PMID: 37497888

Cohort2: Placebo

Administration route	subcutaneous injection
Pts	6
Age	Adult
References	PMID: 37497888

Cohort3: SLN124_dose level 2

Administration route	subcutaneous injection
Dosage	SLN124, 3.0 mg/kg
Pts	6
Age	Adult
References	PMID: 37497888

Cohort4: SLN124_dose level 3

Administration route	subcutaneous injection
Dosage	SLN124, 4.5 mg/kg
Pts	6
Age	Adult
References	PMID: 37497888

Relationship Graph

Overview of Knowledge Graph